Elobixibat rescues severe tirzepatide-induced constipation in a 56-year-old woman, normalizing bowel movements.
Background
Constipation is a prevalent, dose-dependent adverse effect of incretin-based anti-obesity therapies like tirzepatide, often leading to poor patient adherence and discontinuation, thereby sacrificing significant metabolic benefits and weight loss. Current standard-of-care often involves conventional laxatives, which can be ineffective or poorly tolerated in these specific cases. Targeting the ileal bile acid transporter (IBAT) with inhibitors like elobixibat presents a mechanism-based strategy to address the specific motility deficits induced by incretin therapy, offering a potential alternative when other treatments fail.
Study Design
This case report details a 56-year-old woman with obesity (BMI 38.5 kg/m2) who developed severe constipation after escalating tirzepatide to 10 mg weekly. Her bowel movements decreased from 6-8 times weekly (Bristol Stool Chart types 3-5) to 2-3 times weekly (types 1-2), with peak symptoms 2-3 days post-injection. Conventional laxatives (lactulose, psyllium, stimulants, polyethylene glycol) were ineffective or poorly tolerated. Elobixibat was initiated at 10 mg daily before dinner, with continued tirzepatide. The primary endpoint was the resolution of constipation, assessed by bowel movement frequency, consistency, and symptom relief.
Results
Following the first dose of elobixibat, a bowel movement occurred within 20 hours. Stool frequency significantly improved from 2-3 times weekly to 5-6 times weekly initially, then further to 9-10 times weekly in the second week. Transient loose stools were observed, prompting a reduction in elobixibat to 5 mg daily. By week three, bowel movements normalized to 7-8 times weekly (types 3-5), accompanied by improved defecation and complete resolution of painful perianal fissures.
No serious adverse events were observed throughout the treatment period, demonstrating good tolerability for the combined therapy. This targeted intervention allowed the patient to successfully continue her tirzepatide regimen without further gastrointestinal distress.
Key Findings
- Severe constipation developed in a 56-year-old woman on tirzepatide 10 mg weekly, with bowel movements decreasing to 2-3 times weekly.
- Conventional laxatives failed to alleviate symptoms, leading to painful perianal fissures.
- Initiation of elobixibat 10 mg daily resulted in a bowel movement within 20 hours.
- Bowel frequency normalized to 7-8 times weekly (types 3-5) by week three, with resolved perianal symptoms.
- No serious adverse events were observed with the combined tirzepatide and elobixibat therapy.
Why It Matters
This case highlights a critical solution for a common and debilitating side effect of highly effective anti-obesity medications. Elobixibat offers a targeted rescue therapy for incretin-induced severe constipation, potentially improving patient adherence to tirzepatide and similar therapies. This allows individuals to sustain the significant weight loss and metabolic improvements offered by these drugs, which are often discontinued due to GI intolerance. For peptide users, this suggests a specific, mechanism-based approach to manage a challenging adverse event, potentially integrating elobixibat 5-10 mg daily as a protocol adjunct when conventional laxatives prove insufficient for GLP-1R/GIPR agonist-induced constipation. Further prospective evaluation is recommended to validate this strategy.
tirzepatide
elobixibat
constipation
obesity
glp-1-agonist
gip-agonist